MEK inhibitors in non-V600 BRAF mutations and fusions
Douglas B. Johnson, Caroline A. Nebhan, Marcus Smith Noel
Abstract
// Douglas B. Johnson 1 , Caroline A. Nebhan 1 and Marcus S. Noel 2 1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA 2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA Correspondence to: Douglas B. Johnson, email: [email protected] Keywords: trametinib; MEK; BRAF; atypical; fusion Received: October 09, 2020     Accepted: October 13, 2020     Published: November 03, 2020 Copyright: © 2020 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.